Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Unicycive Therapeutics Inc logo

    Unicycive Therapeutics Inc

    US$7.69

    US$170.0m

    6.81%

    1193.09%

    Transparent research score

    MaveScore

    A research prioritization score from 0 to 100. It is model output for watchlist review, not personalized financial advice.

    19 Low confidence High
    Fundamentals Dec 31, 2025
    Price Jun 10, 2026
    Confidence High

    Stored data quality

    Freshness and coverage checks

    Latest stored fundamentals and price inputs are recent enough for normal research review.

    16/16 Current stored snapshot
    Fundamental period Dec 31, 2025 162 days old
    Price snapshot Jun 10, 2026 1 day old
    Input coverage 16/16 Stored fields powering this model output
    Confidence impact 0 gaps Missing fields reduce confidence and can limit signal detail

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    4/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    6/25 Weak

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    0/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    8/15 Mixed

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    1/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Financial strength rewards durable profitability, margins, and positive free cash flow.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Unicycive Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

    Unicycive Therapeutics Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Unicycive Therapeutics Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    News Image
    Looking For A Good Stock? Let This Unicycive Therapeutics Inc (NASDAQ: UNCY) Analysis Help.
    14 minutes ago
    News Image
    Kaplan Fox & Kilsheimer LLP is Investigating Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law Violations | FinancialContent
    11 hours ago
    News Image
    Unicycive Receives FDA CRL for New Drug Application
    11 hours ago

    Unicycive Therapeutics Inc Competitors

    Unicycive Therapeutics Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Unicycive Therapeutics Inc

    US$7.69

    US$170.0m

    6.81%

    1193.09%